Author, as appears in the article.: Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Goday, A; Martínez, JA; Alonso-Gómez, AM; Fernández-Barceló, O; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majema, L; Riquelme-Gallegop, B; Martín-Sánchez, V; Pintó, X; Delgado-Rodriguez, M; Matía, P; Vidal, J; Cardenas-Salas, JJ; Daimiel, L; Ros, E; Toledo, E; Manzanares, JM; Gonzalez-Monge, I; Muñoz, MA; Martinez-Urbistondo, D; Tojal-Sierra, L; Muñoz-Bravoaf, C; Miralles-Gisbert, S; Martin, M; García-Ríos, A; Castro-Barquero, S; Fernández-García, JC; Santos-Lozano, JM; Basterra-Gortari, FJ; Gutiérrez-Carrasquilla, L; Guillem-Saiz, P; Satorres, A; Abete, I; Sorto-Sanchez, C; Díez-Espino, J; Babio, N; Fitó, M; Tur, JA
Department: Bioquímica i Biotecnologia
URV's Author/s: Babio Sánchez, Nancy Elvira / Manzanares Errazu, José María / Salas Salvadó, Jorge
Keywords: Metabolic syndrome Glucagon-like peptide 1 agonists Glp-1ra Dpp-4i Antidiabetic drug 4-dipeptidyl peptidase inhibitors sitagliptin questionnaire physical-activity pharmacokinetics medication iv inhibitor insulin glucagon-like peptide 1 agonists glp-1ra glp-1 dpp-4i double-blind 4-dipeptidyl peptidase inhibitors
Abstract: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients.Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires.MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: -1.7 mg/dL(± 13.5); ∆ metformin: - 2.5(± 23.9) mg/dL; ∆ DPP-4I: - 4.5(± 42.6); mg/dL ∆ GLP-1RA: - 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: - 0.1(± 0.7) %; ∆ DPP-4I: - 0.1(± 1.0) %; ∆ GLP-1RA: - 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: -0.8(± 1.6) kg/m2; ∆ metformin: - 0.8(± 1.5) kg/m2; ∆ DPP-4I: - 0.6(± 1.3) kg/m2; ∆ GLP-1RA: - 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: -2.8(± 5.2) cm; ∆ metformin: - 2.6(± 15.2) cm; ∆ DPP-4I: - 2.1(± 4.8) cm; ∆ GLP-1RA: - 2.4(± 4.1) cm.In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Thematic Areas: Saúde coletiva Química Pharmacology & pharmacy Pharmacology Odontología Medicine, research & experimental Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Interdisciplinar Farmacia Engenharias iii Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Ciência de alimentos Ciência da computação Biotecnología Biodiversidade Astronomia / física
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: josemaria.manzanares@urv.cat jordi.salas@urv.cat josemaria.manzanares@urv.cat nancy.babio@urv.cat
Author identifier: 0000-0003-2700-7459 0000-0003-3527-5277
Record's date: 2024-08-03
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.sciencedirect.com/science/article/pii/S0753332223003499?via%3Dihub
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Biomedicine & Pharmacotherapy. 161 114561-114561
APA: Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Goday, A; Martínez, JA; Alonso-Gómez, AM; (2023). Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomedicine & Pharmacotherapy, 161(), 114561-114561. DOI: 10.1016/j.biopha.2023.114561
Article's DOI: 10.1016/j.biopha.2023.114561
Entity: Universitat Rovira i Virgili
Journal publication year: 2023
Publication Type: Journal Publications
Repositori URV